Clinical trials
Acute Leukemia clinical trials
Below are recruiting acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 943 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT07474051Enrolling by invitation
Long-term follow-up for CAR-T cell therapy patients
This study tracks people who received a specific CAR-T cell therapy made by AvenCell. The goal is to monitor their health over time to better understand long-term effects.
BerlinAges Any age - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT07469592Recruiting
Mindfulness and music therapy for stem cell transplant patients
This trial tests a combined mindfulness and music therapy program delivered through an app or website. It aims to help patients cope with the stress of stem cell transplant for blood cancers like leukemia or lymphoma.
Miami, FloridaAges 18 years+ - NCT04093570Enrolling by invitationPhase 2
Extension study for people continuing ASTX727 from a prior trial
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
Fountain Valley, CaliforniaAges 18 years+ - NCT03999723RecruitingPhase 2
Test azacitidine with vitamin C to improve DNA changes
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
AalborgAges 18 years+ - NCT04581512RecruitingPhase 1/Phase 2
Safety study of EP0042 for certain AML patients
This Phase 1/2 study tests how safe and tolerable EP0042 is, and looks at patients with a specific type of AML that has come back or did not respond to prior treatment. You may be considered if your AML diagnosis is confirmed and your lab tests, overall health, and medication history fit the study rules.
Perth, Western AustraliaAges 18 years+ - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70 - NCT05184842RecruitingPhase 2
Weekly low-dose decitabine plus venetoclax for MDS or AML
This Phase 2 study tests a gentler weekly combination of two medicines—decitabine and venetoclax—for people with MDS, AML, or MDS/MPN. The goal is to improve blood counts and disease control while reducing side effects compared with more harsh treatments.
Sacramento, CaliforniaAges 18 years+ - NCT05305859RecruitingPhase 2
Venetoclax, chidamide, and azacitidine for hard-to-treat AML
This Phase 2 trial tests whether adding three medicines—venetoclax, chidamide, and azacitidine—can help adults whose AML has come back or did not respond to treatment. It may help shrink or control the leukemia and improve outcomes for people who fit the study’s health and lab requirements.
Xiamen, FujianAges 18 years+ - NCT05807932RecruitingPhase 1/Phase 2
Venetoclax added to conditioning before stem cell transplant
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
Aachen, North Rhine-WestphaliaAges 18 years+ - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
Phoenix, ArizonaAges Up to 1 year - NCT06508775Recruiting
Long-term checkup for Miltenyi cell therapy patients
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
BerlinAges Any age - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06919393Recruiting
A study for adults with triple negative B-cell ALL
This study is for adults with B-cell acute lymphoblastic leukemia (ALL) that does not have three specific gene changes (called BCR-ABL1, TCF3-PBX1, and MLL-AF4). The study will look at people who are newly diagnosed or who have had their cancer come back.
Meldola, FCAges 18 years+ - NCT02443831RecruitingPhase 1
CAR T-cell immunotherapy for high-risk childhood leukemia
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
LondonAges Up to 24 years - NCT06697275Recruiting
Virtual reality to ease port needle insertion in children with leukemia
This trial tests whether using a virtual reality mask can help reduce pain or fear when children with leukemia get a needle placed into their implantable port (a small device under the skin used for medicines). The goal is to see if it makes the procedure more comfortable.
BordeauxAges 6–16 - NCT07238712RecruitingPhase 2
New drug combo for high-risk blood cancer transplant
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
Saint PetersburgAges 18–70 - NCT06099366RecruitingPhase 2
Chemo for standard-risk childhood leukemia
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
Seoul, Other (Non U.s.)Ages 1–9 - NCT03058588Recruiting
Genetic testing study for inherited AML or MDS risk
This study uses advanced DNA testing to look for inherited gene changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It may help explain whether your illness could be part of a family-linked risk syndrome, which can guide treatment and family planning.
BresciaAges Any age - NCT06765876RecruitingEarly Phase 1
CAR T-cell therapy for CD123+ blood cancers
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called CD123 on cancer cells. It is for people with certain blood cancers (AML, MDS-IB2, BPDCN, or ALL) that have come back or not responded to other treatments.
PragueAges 18–70 - NCT06934382RecruitingPhase 1
CAR-T cell therapy for relapsed T-cell leukemia or lymphoma
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
Philadelphia, PennsylvaniaAges birth–29 years - NCT07224100RecruitingPhase 2
Chemo plus targeted drug for newly diagnosed Ph+ ALL
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
Seattle, WashingtonAges 18 years+ - NCT03964506RecruitingEarly Phase 1
Hyperbaric oxygen plus donor stem cell transplant for blood cancers
This early-phase trial studies whether breathing pure oxygen in a pressurized chamber, along with a donor stem cell transplant, can improve outcomes for certain blood cancers. It may help by supporting the body during transplant and recovery, but it is still being tested for safety and effectiveness.
Rochester, New YorkAges 18–75
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia?
- Yes. Clin2 currently lists 943 recruiting acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.